1Q Revenues: $1.3 billion (+6%)
1Q Earnings: $90.2 million (+87%)
Comments: Product Development revenues grew 9% to $770.8 million, with growth in core clinical services in North America, clinical trial support services, and increases in global labs, and the Novella acquisition in 2013. Integrated Healthcare Service revenues were up 8% to $234.5 million, primarily due to increases in Japan and North America, as well as growth in real-world and late phase research services. Net new business wins were $1.27 billion in the quarter, representing a book-to-bill ratio of 1.27, contributing to an ending backlog of $10.1 billion at March 31st.